文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Droy B F, Goodrich M S, Lech J J, Kleinow K M

Department of Veterinary Physiology, Pharmacology and Toxicology, Louisiana State University, School of Veterinary Medicine, Baton Rouge 70803.

Xenobiotica. 1990 Feb;20(2):147-57. doi: 10.3109/00498259009047150.

Uptake, bioavailability, tissue disposition, and elimination of 14C were examined in rainbow trout following intravascular and per os dosing of 14C-ormetoprim (8 mg/kg). 2. Plasma clearance was rapid following a single i.v. dose (t1/2 alpha = 0.54 h, t1/2 beta = 17.5 h) with an apparent volume of distribution (Vss) of 4.85 l/kg. An increase in both t1/2 alpha (0.67 h) and t1/2 beta (36.7 h) was seen following multiple i.v. doses (steady state). 3. Oral dispositional studies revealed the highest concentration of OMP in bile, kidney and liver, indicating significant renal and hepatic extraction. Significant OMP residues were seen in skin (0.90 p.p.m.) and muscle (0.15 p.p.m.) at 38 days. 4. Peak absorption time of orally administered OMP was 12 h with an apparent bioavailability of 87%. 5. Intravascularly administered OMP was 33% and 31% protein-bound at 1 and 6 h respectively, and binding was non-specific and non-saturable by Scatchard analysis.

在虹鳟鱼经血管内和口服给予14C-奥美普明（8毫克/千克）后，检测了14C的摄取、生物利用度、组织分布和消除情况。2. 单次静脉注射剂量后血浆清除迅速（t1/2α = 0.54小时，t1/2β = 17.5小时），表观分布容积（Vss）为4.85升/千克。多次静脉注射剂量（稳态）后，t1/2α（0.67小时）和t1/2β（36.7小时）均增加。3. 口服处置研究显示，胆汁、肾脏和肝脏中奥美普明浓度最高，表明肾脏和肝脏有显著摄取。在38天时，皮肤（0.90 ppm）和肌肉（0.15 ppm）中可见显著的奥美普明残留。4. 口服奥美普明的峰值吸收时间为12小时，表观生物利用度为87%。5. 血管内给予的奥美普明在1小时和6小时时分别有33%和31%与蛋白质结合，通过Scatchard分析，结合是非特异性且不饱和的。

Droy B F, Goodrich M S, Lech J J, Kleinow K M

Department of Veterinary Physiology, Pharmacology and Toxicology, Louisiana State University, School of Veterinary Medicine, Baton Rouge 70803.

Xenobiotica. 1990 Feb;20(2):147-57. doi: 10.3109/00498259009047150.

Uptake, bioavailability, tissue disposition, and elimination of 14C were examined in rainbow trout following intravascular and per os dosing of 14C-ormetoprim (8 mg/kg). 2. Plasma clearance was rapid following a single i.v. dose (t1/2 alpha = 0.54 h, t1/2 beta = 17.5 h) with an apparent volume of distribution (Vss) of 4.85 l/kg. An increase in both t1/2 alpha (0.67 h) and t1/2 beta (36.7 h) was seen following multiple i.v. doses (steady state). 3. Oral dispositional studies revealed the highest concentration of OMP in bile, kidney and liver, indicating significant renal and hepatic extraction. Significant OMP residues were seen in skin (0.90 p.p.m.) and muscle (0.15 p.p.m.) at 38 days. 4. Peak absorption time of orally administered OMP was 12 h with an apparent bioavailability of 87%. 5. Intravascularly administered OMP was 33% and 31% protein-bound at 1 and 6 h respectively, and binding was non-specific and non-saturable by Scatchard analysis.

在虹鳟鱼经血管内和口服给予14C-奥美普明（8毫克/千克）后，检测了14C的摄取、生物利用度、组织分布和消除情况。2. 单次静脉注射剂量后血浆清除迅速（t1/2α = 0.54小时，t1/2β = 17.5小时），表观分布容积（Vss）为4.85升/千克。多次静脉注射剂量（稳态）后，t1/2α（0.67小时）和t1/2β（36.7小时）均增加。3. 口服处置研究显示，胆汁、肾脏和肝脏中奥美普明浓度最高，表明肾脏和肝脏有显著摄取。在38天时，皮肤（0.90 ppm）和肌肉（0.15 ppm）中可见显著的奥美普明残留。4. 口服奥美普明的峰值吸收时间为12小时，表观生物利用度为87%。5. 血管内给予的奥美普明在1小时和6小时时分别有33%和31%与蛋白质结合，通过Scatchard分析，结合是非特异性且不饱和的。